Reduced levonorgestrel concentrations from the levonorgestrel contraceptive implant was previously seen when given concomitantly with efavirenz. We sought to assess whether single nucleotide polymorphisms (SNPs) in genes involved in efavirenz and nevirapine metabolism were linked to these changes in levonorgestrel concentration. SNPs in CYP2B6, CYP2A6, NR1I2, and NR1I3 were analyzed. Associations of participant demographics and genotype with levonorgestrel pharmacokinetics were evaluated in HIV-positive women using the levonorgestrel implant plus efavirenz-or nevirapinebased antiretroviral therapy (ART), in comparison to ART-na€ ıve women using multivariate linear regression. Efavirenz group: CYP2B6 516G>T was associated with lower levonorgestrel log 10 C max and log 10 AUC. CYP2B6 15582C>T was associated with lower log 10 AUC. Nevirapine group: CYP2B6 516G>T was associated with higher log 10 C max and lower log 10 C min . Pharmacogenetic variations influenced subdermal levonorgestrel pharmacokinetics in HIV-positive women, indicating that the magnitude of the interaction with non-nucleoside reverse transcriptase inhibitors (NNRTIs) is influenced by host genetics.
fetal risk during in utero EFV exposure, [9] [10] [11] and subsequently due to recent WHO recommendations for universal use of ART irrespective of CD41 cell count. 12 Considered an alternate first-line option, nevirapine (NVP), is still used by many women in low-and middle-income countries. 8 In light of this, identifying safe and efficacious combinations of both therapies with hormonal contraceptives in HIV-positive women is a critical public health priority.
We previously described a significant drug-drug interaction between the LNG implant and EFV-based ART in HIV-positive Ugandan women, which resulted in 47% lower LNG concentrations compared to control participants, and a high rate of unintended pregnancy, in women receiving EFV-based ART (3 (15%) of 20 participants). 13 Induction of CYP3A4-and CYP3A5-mediated metabolism of LNG is the proposed mechanism of the observed interaction with EFV. No pharmacokinetic interaction or unintended pregnancies were observed in women receiving NVP-based ART within the same study. These findings are supported by a retrospective cohort study of Kenyan women that found a 3-fold higher adjusted pregnancy incidence in HIVpositive women receiving the implant plus EFV-based ART compared to those receiving NVP-based ART. 14 LNG, EFV, and NVP are substrates of cytochrome P450 (CYP) enzymes; LNG is metabolized by CYP3A4 and CYP3A5, 15 EFV is metabolized by CYP2B6 with minor contributions from CYP2A6, CYP3A4, and UGT2B7, 16, 17 while NVP is metabolized by CYP2B6, CYP3A4, and partially by CYP2D6. 18, 19 The nuclear receptors NR1I2 and NR1I3 are known to regulate the expression and activity of several CYPs, including CYP2B6 and CYP3A4. Multiple SNPs in both NR1I2 and NR1I3 genes have been linked to variation in expression of CYP3A4 and CYP2B6, [20] [21] [22] which may alter the pharmacokinetics (PK) of substrate drugs. Activation of NR1I2 and NR1I3 results in upregulation of target CYPs and alters the PK of their substrates. Both phenomena have been demonstrated for EFV and NVP. 23, 24 CYP2B6 516G>T has previously been associated with higher EFV and NVP plasma concentrations. [25] [26] [27] [28] [29] [30] [31] Notably, several polymorphisms associated with EFV and NVP PK are found more commonly within African populations compared to Caucasians or Asians. 1, 28, [32] [33] [34] [35] The primary objective of this secondary study analysis was to ascertain the contributory effect of SNPs in key genes of interest in LNG, EFV, and NVP metabolism (CYP2B6, CYP2A6, NR1I2, and NR1I3) on plasma LNG PK when the subdermal implant is given in combination with EFV-or NVP-based ART (EFV and NVP groups, respectively) in HIV-positive women. The control group of the primary study was not included in this pharmacogenetics analysis because the purpose of the study was to investigate the genetic basis for the interaction between NNRTIs and LNG. Since these SNPs have been shown to influence non-nucleoside reverse transcriptase inhibitors (NNRTI) PK, our underlying hypothesis was that there would be consequences of different NNRTI concentrations for the degree of CYP3A induction, and therefore a genetic basis for the subsequent magnitude of the interaction with LNG.
RESULTS
All women in the EFV and NVP groups from the primary study were included in this analysis (n 5 40). 13 Patient characteristics and genotype frequencies are summarized in Table 1 . The median (interquartile range (IQR)) age and weight of all patients was 31 years (29-34 years) and 59 kg (53-68 kg). All SNPs were in Hardy-Weinberg equilibrium, except CYP2B6 15582C>T (rs4803419) (X 2 5 20.62, P < 0.001) and NR1I3 540C>T(rs2307424) (X 2 5 12.36, P < 0.001), which compromises their interpretation. Univariate and multiple regression analysis for LNG PK parameters based on EFV and NVP groups are presented in Table 2 . All regression results can be found in Supplementary Table 1 .
Levonorgestrel, efavirenz, and nevirapine pharmacokinetics LNG C max , T max , C min , and AUC 0-24week are summarized by study group and SNP in Table 3 . EFV C 12-14h (mg/L) was 76% higher in homozygous CYP2B6 516 TT participants compared to those who were homozygous for the G allele. Within the NVP group NVP C 11-13h (mg/L) was 5% lower in heterozygous CYP2B6 516 CT participants compared to homozygotes for the G allele.
Efavirenz group
All patients in the EFV group (n 5 20) received EFV 600 mg daily plus two NRTIs for a median (IQR) of 10.5 months (6.3-37.8) prior to study entry. After multivariate analysis, CYP2B6 516G>T (rs3745274) was associated with lower log 10 LNG C max (b 5 -0.209, P 5 0.021) and log 10 LNG AUC 0-24weeks (b 5 -0.132, P 5 0.023). This meant that LNG C max median values were 692.8, 402.4, and 200.6 pg/mL in the GG, GT, and TT genotype groups, respectively (71% difference between homozygote groups) and LNG AUC 0-24weeks median values were 10,114.6, 6,311.8, and 3,622.1 pg*wk/mL in the GG, GT, and TT genotype groups, respectively (64% difference between homozygote groups). CYP2B6 15582C>T (rs4803419) was associated with lower log 10 LNG AUC 0-24weeks (b 5 -0.163, P 5 0.021), resulting in LNG AUC 0-24weeks median values of 10,114.6 and 7,754.4 pg*wk/mL in the CC and CT genotype groups, respectively (23% difference between groups). Figure 1 illustrates the LNG AUC 0-24weeks within the EFV group according to these genotypes. In addition to these genetic associations, age was inversely associated with log 10 LNG AUC 0-24weeks (b 5 -0.018 per 1 year, P 5 0.039) ( Table 2) .
Consistent with previous reports, through univariate linear regression analysis, CYP2B6 516G>T was associated with higher EFV concentration (b 5 0.269, P 5 0.011), meaning that C 12-14h values were 2.1, 2.6, and 8.7 mg/L in GG, GT, and TT genotype groups, respectively (76% difference between homozygote groups). Additionally, higher EFV C 12-14h (log 10 mg/L) was associated with lower LNG log 10 AUC 0-24week (b 5 -0.030, P 5 0.003).
Nevirapine group
Patients in the NVP group (n 5 20) received NVP 200 mg twice daily plus two NRTIs for a median (IQR) of 30.5 months (13.5-80.3) prior to study entry. CYP2B6 516G>T (rs3745274) was associated with higher log 10 LNG C max (b 5 0.103, P 5 0.034) and log 10 LNG C min (b 5 0.115, P 5 0.048). Resulting in LNG C max median values of 1310.8 and 1449.5 pg/mL in the GG and GT genotype groups, respectively (10% difference between homozygote groups) and LNG C min median values of 553.7 and 562.6 pg/mL in the GG and GT genotype groups (2% difference between groups). NR1I2 63396C>T was associated with delayed LNG T max (b 5 1.623, P 5 0.003) with a median value of 1.0, 1.0, and 6.5 weeks in the CC, CT, and TT genotype groups. Additionally, log 10 weight (b 5 -15.910, P 5 0.002) and albumin concentration at baseline (b 5 -0.340, P 5 0.003) were associated with shorter LNG T max . Log 10 SHBG was associated with higher log 10 LNG AUC 0-24weeks (b 5 0.484, P 5 0.004), log 10 LNG C min (b 5 0.522, P 5 0.011) and log 10 LNG C max (b 5 0.469, P 5 0.007). Age was associated with higher log 10 LNG C max (b 5 0.013, P 5 0.044) ( Table 2) .
No other genetic associations were observed in any of the groups; however, the sample size was insufficient to robustly assess the CYP2B6 983T>C variant (rs28399499).
Pharmacodynamic outcome in the EFV group
Three women in the EFV group became pregnant between study weeks 36 and 48 (3 (15%) of 20 participants). Pharmacogenetic characteristics of these three patients were as follows for the statistically significant genotypes within the EFV group: One woman was both homozygous TT for CYP2B6 516G>T (rs3745274) and heterozygous CT for CYP2B6 15582C>T (rs4803419). She was the only patient who possessed both of these genotypes in the study group, and her LNG concentration at the study visit prior to pregnancy (week 36) was 122 pg/mL (LNG AUC 0-24weeks 3,622 pg*wk/mL). The other two women were heterozygous CT for CYP2B6 516G>T and homozygous CC for CYP2B6 1582 C>T. They were the only patients in the EFV group who possessed these genotypes, and their LNG concentration prior to pregnancy (week 36) were 299 and 303 pg/ mL (LNG AUC 0-24weeks 10,115 and 8,500 pg*wk/mL), respectively.
DISCUSSION
The impact of this investigation is greatest for women receiving a combination of EFV-based ART with a LNG subdermal implant. Women receiving this drug combination are at risk for suboptimal LNG exposure, which results in a higher rate of contraceptive failures. 13, 14 For women who are heterozygous or homozygous for CYP2B6 516G>T or CYP2B6 15582C>T, which was associated with lower LNG AUC when combined with EFV, this drug-drug interaction will be more pronounced. This was evidenced by the three patients who became pregnant in the EFV group: all possessed at least one of these genotypes and the patient who possessed both significant genotypes had the lowest LNG exposure of any study participant. Importantly, nine additional women in the EFV group were heterozygous for either CYP2B6 516G>T or CYP2B6 15582C>T, and had LNG exposure (median LNG AUC 0-24weeks 6,831 pg*wk/mL), consistent with those women who became pregnant, indicating that they were also at risk for contraceptive failure. We hypothesize that high EFV plasma concentrations associated with these SNPs may result in greater EFV induction of CYP3A4, resulting in increased LNG metabolism and lower LNG exposure in the patients who were heterozygous or homozygous for CYP2B6 516G>T or CYP2B6 15582C>T. Further contributing to this effect may be the modest inhibitory effect of LNG on CYP2B6. 36, 37 It is possible that LNG may inhibit CYP2B6 activity, resulting in high EFV concentrations and further inhibition of CYP3A4.
Within the NVP group, the significant association between CYP2B6 516G>T and higher LNG log 10 C max and LNG log 10 C min is surprising, given that NVP is an inducer of CYP3A4, the enzyme believed to be primarily responsible for LNG ARTICLES metabolism. In a previous study of three HIV-positive Malawian women receiving 30 lg ethinyl estradiol / 300 lg norgestrel (a racemic mixture of LNG and dextronorgestrel) and NVP-based ART, higher LNG exposure was also observed compared to HIV-uninfected women. 38 Notably, two of the three women were heterozygous for CYP2B6 516G>T. Furthermore, CYP2B6 516G>T has been associated with elevated NVP concentrations in previous studies. 1, 39 Therefore, the association between CYP2B6 516G>T and LNG PK parameters observed in our study could be attributed to NVP-mediated inhibition of LNG metabolism by CYP3A4, or potential inhibition of CYP3A5. However, this result must be interpreted with caution, given that overall exposure (as measured by AUC) was not associated with the same SNP. Further investigation is required to determine the mechanism underpinning this finding.
We observed an association between NR1I2 63396C>T (rs2472677) and delayed LNG T max in patients on NVP, which has the potential to result in suboptimal LNG concentrations. Previously, NR1I2 63396C>T (in linkage disequilibrium (LD) with 63704G>A, 63813(CAAA)n/(CA)n, and 65104T>C) has been associated with higher NR1I2 expression, elevated CYP3A4 expression, and unboosted atazanavir plasma concentrations. 23, 40, 41 NR1I2 63396C>T may be directly or indirectly associated with inducibility of CYP3A4 and hence reduced LNG metabolism. This is supported by observations in primary human hepatocytes where the 63396T allele was associated with higher basal activity but lower rifampicin-mediated inducibility of CYP3A4. 23 LNG pharmacokinetics demonstrate high interindividual variability, often attributed to variations in protein binding 42 and bodyweight. [43] [44] [45] Although we did not observe a consistent association with weight and LNG PK, this may be related to the lower median body weight of HIV-infected Ugandan women compared to those in other studied populations. LNG is highly protein-bound to sex hormone-binding globulin (SHBG) and albumin. 42 Elevated log 10 SHBG concentration has previously been associated with higher serum LNG concentration. 46 However, the observed association of log 10 SHBG concentration at baseline with higher LNG log 10 C max , LNG log 10 C min , and LNG log 10 AUC 0-24weeks , and of albumin concentration at baseline with lower T max within the NVP group, may reflect some influence of baseline protein binding on overall LNG exposure.
Limitations of this study include a relatively small sample size, particularly related to CYP2B6 15582C>T(rs4803419) and NR1I3 540C>T(rs2307424), as both SNPs were not in HardyWeinberg equilibrium. In addition, the consequences of the T max associations are unclear, but should in any case be interpreted cautiously given the intermittent measurement of LNG PK during the study period.
Our study demonstrates pharmacogenetic associations with LNG PK when administered as an LNG subdermal implant in HIV-positive women receiving EFV-or NVP-based ART. Even with the EFV interaction with LNG, effectiveness of the LNG subdermal implant may still be higher than that for oral contraception due to improved medication adherence. 14, 47 Notwithstanding, any increased risk of pregnancy during contraception is important, given the impact that unintended pregnancy has for women living with HIV. Based on our findings, screening for SNPs associated with low LNG exposure in patients receiving EFV represents a novel approach to identify women at the highest risk for an unintended pregnancy. Added pharmacogenetic knowledge would allow clinicians to personalize counseling of women on their choice of a contraceptive method based on individualized risks and benefits. Overall, this study highlights the potential role of affordable, accessible and clinically relevant pharmacogenetic screening in resource-constrained settings. Specifically, future studies with larger populations and a more diverse range of ethnicities should focus on prospective evaluation of the relationship between pharmacogenetics and the effectiveness of the LNG implant in the presence of EFV-related drug-drug interactions. 
METHODS

Aim of the study
The aim was to assess the association between LNG PK and SNPs in CYP2B6, CYP2A6, NR1I3, and NR1I2 in Ugandan HIV-positive women participating in a drug-drug interaction PK study. 13 Ethical approval All study procedures followed the Helsinki Declaration of 1975 and were approved by Ethics Boards at the Joint Clinical Research Centre Kampala, Uganda National Council for Science and Technology, and the University of Nebraska Medical Centre. The study was registered on clinicaltrials.gov (NCT01789879).
Study design and cohort
This was a prospective PK evaluation of HIV-positive Ugandan women receiving EFV-based ART (EFV group, n 5 20), NVP-based ART (NVP group, n 5 20), or ART-na€ ıve (n 5 17). For the pharmacogenetic study, all participants in the EFV and NVP group were included (n 5 40) and the ART-na€ ıve group was excluded. The two-rod (75 mg/rod) LNG subdermal implant was inserted in all patients upon study entry. Inclusion criteria for the EFV and NVP groups included prescription of EFV or NVP plus two NRTIs for 30 days or longer and an HIV-RNA of <400 copies/mL. 48 Sample and data collection Over a total of 48 weeks, a plasma sample was collected at weeks 1, 4, 12, 24, 36, and 48 to assess LNG, NVP, and EFV PK. Follow-up was interrupted for nine subjects between weeks 36-44 after three pregnancies were identified in the EFV group. The primary endpoint for the PK analysis was 24 weeks. Timing of blood sample collection for the EFV group was based on EFV mid-dosing interval at 12-14 h postdose and for the NVP group based on the end dosing interval of 11-13 h postdose. PK parameters included in this analysis were area under the concentration time curve (AUC) from entry to week 24 (AUC 0-24weeks ), maximum concentration (C max ), time to C max (T max ), and minimum concentration (C min ). C max and C min represent the highest and lowest concentrations observed over the entire study period. AUC was calculated using the trapezoidal rule (Phoenix WinNonlin, Certara). LNG concentrations were analyzed by a validated LC-MS/MS method; EFV and NVP plasma concentrations were determined using high-performance liquid chromatography (HPLC) assays with ultraviolet detection as previously outlined by Scarsi et al.
13
Genotyping Genomic DNA was extracted from whole blood through use of the manufacturers protocol (E.Z.N.A Blood DNA Mini Kit; Omega bio-tek; Norcross, GA). Extracted DNA was quantified using NanoDrop (Thermo Fisher Scientific, Wilmington, DE). Genotyping was completed using realtime allelic discrimination polymerase chain reaction (PCR) assay on a DNA Engine Chromo4 system (Bio-Rad Laboratories, Hercules, CA). The PCR protocol followed denaturation at 958C for 10 min, followed by 50 cycles of amplification at 928C for 15 sec and annealing at 608C for 1 min 30 sec. Taqman Genotyping Master mix and assays CYP2B6 516G>T (rs3745274, catalog number C___7817765_60), CYP2B6 983T>C (rs28399499, catalog number C__60732328_20), CYP2B6 15582C>T (rs4803419, catalog number C___7817764_10), CYP2A6 -48A>C (rs28399433, catalog number C__30634332_10) CYP2A6*9B 1836G>T (rs8192726, catalog number C__29560333_20) NR1I2 63396C>T (rs2472677, catalog number C_2607845), NR1I3 540C>T (rs2307424, catalog number C__25746794_20) and NR1I3 1089T>C (rs3003596, catalog number C__16194070_10) were purchased from Life Technologies (Paisley, Renfrewshire, UK). Opticon Monitor v. 3.1 software (Bio-Rad Laboratories) was used to obtain allelic discrimination plots and identify genotypes.
Statistical analysis
Compliance with Hardy-Weinberg equilibrium was tested using previously outlined methods. 49 Genotypes were coded for regression analyses as 0 5 homozygous common allele, 1 5 heterozygous, and 2 5 homozygous variant allele. Categorical variables were described using relative frequencies, while continuous variables were described using median and IQR. The Shapiro-Wilk test was used to test for normality, with P 0.05 considered statistically significant. A univariate analysis through linear enter regression was carried out in order to identify independent variables associated with LNG PK parameters within all patients, the EFV group, and the NVP group. Variables with P 0.2 for the univariate analysis were carried through to a linear backwards multivariate analysis were P 0.05 was classed as statistically significant. All statistical analyses were carried out using IBM SPSS Statistics v. 22 (IBM, Armonk, NY). All charts were produced using GraphPad Prism 6 (GraphPad Software, La Jolla, CA).
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